Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases
MWN-AI** Summary
Orum Therapeutics, a biotechnology company focused on degrader-antibody conjugates (DACs), has successfully raised approximately US$100 million (145 billion KRW) through convertible preferred stock financing. This fundraising round was spearheaded by returning investor KB Investment and included participation from existing stakeholders like IMM Investment, Woori Venture Partners, and Stassets Investment, alongside new investors such as Weiss Asset Management and Korea Investment Partners. The backing from both seasoned and new investors underscores confidence in Orum's innovative approach to drug development aimed at treating severe diseases, particularly cancer.
The funds will primarily be allocated to advance Orum's therapeutic programs toward clinical evaluations, including ORM-1153 and other promising candidates in their pipeline. The financing will also facilitate the development of novel payloads that enhance the efficacy of their DACs, broadening their operational capabilities. According to Dr. Sung Joo Lee, Orum's CEO, the investment will propel their mission to create precise, targeted therapeutics that harness powerful degrader payloads, thereby improving treatment options for patients.
Orum's unique Dual-Precision Targeted Protein Degradation (TPD²®) technology combines targeted protein degraders with cell-selective antibody delivery, enabling a focused approach to degrading harmful intracellular proteins within cancer cells. This capability positions Orum to lead advancements in the field, as they expand their research into various payload classes while refining their DAC platforms. Overall, this funding marks a significant step in elevating Orum Therapeutics’ clinical development efforts and supporting their goal of delivering meaningful innovations in oncology and other serious medical conditions.
MWN-AI** Analysis
Orum Therapeutics (KRX: 475830), a biotechnology firm dedicated to advancing targeted protein degradation therapies, has just secured approximately US$100 million in funding, a significant move that promises to propel its research and development efforts in the burgeoning field of degrader-antibody conjugates (DACs). This investment includes strong backing from both existing and new investors, underscoring confidence in Orum's innovative strategies and long-term viability.
With the funding primarily aimed at advancing its lead compound, ORM-1153, and augmenting its DAC platforms, Orum exhibits a strong pathway to clinical development. The key here for investors is to recognize the company’s strategic focus on enhancing its scientific infrastructure and expanding into novel payload classes, which positions Orum as a potential leader in oncology and other serious diseases. Given the anticipated growth trajectory, investors should view Orum's established partnerships with reputable venture capital firms, like KB Investment and IMM Investment, as a validation of its scientific direction.
Financially, Orum’s stock has the potential for upward movement, catalyzed by successful clinical evaluations and potential future partnerships. However, investors should remain cautious; biotechnology is inherently risky, with considerable uncertainties tied to research outcomes and market competition. Successfully navigating these challenges could lead to significant returns, especially if Orum can deliver on its promise of innovative DAC therapies.
In conclusion, while Orum Therapeutics is at an inflection point with robust backing and ambitious goals, investors are advised to monitor developments closely, particularly around clinical trials and market reception of their emerging therapies. A diversified approach, balancing excitement in biopharma investments with prudent risk assessment, will be essential for optimal portfolio management in this sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations
- Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that it secured 145 billion KRW (approximately US$100 million) in convertible preferred stock investments. This round is led by returning investor KB Investment and includes other existing investors, IMM Investment, Woori Venture Partners and Stassets Investment. New investors include Weiss Asset Management, a Boston-based global investment firm, and Korea Investment Partners, a major institutional venture investor with a strong track record in biotech investment. Additional new investors in this round are DSC Investment, Company K Partners, AON Investment, and DAYLI Partners.
“Our mission is to deliver degrader-antibody conjugate therapeutics that apply powerful degrader payloads with antibody-targeted precision to improve the treatment of cancer and other serious diseases,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “This investment supports the next stage of our growth as we prepare to advance our next therapeutic programs towards clinical evaluation, develop additional novel payloads, and continue to build platforms that can generate differentiated drug candidates across oncology and beyond. We appreciate the confidence of both new and existing investors who share our commitment to delivering meaningful innovation for patients.”
This investment supports the advancement of ORM-1153 and additional programs in Orum’s pipeline and continued refinement of the Company’s DAC platforms, including development of additional novel payload classes beyond GSPT1. It also supports the expansion of Orum’s scientific and operational infrastructure as the Company advances additional targeted DAC programs based on principles of selectivity, potency, and rational payload design. These efforts are foundational to Orum’s strategy to generate differentiated therapeutic DAC programs for oncology and other serious diseases.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum’s novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com .
About KB Investment Co.
KB Investment Co., Ltd. (KBI) is a global venture capital firm backed by KB Financial Group (KRX: 105560, NYSE: KB), Korea’s largest and most influential financial institution. Since its establishment in 1990, KBI has invested across early- to growth-stage companies, building a diversified portfolio of more than 500 companies spanning biotechnology, healthcare, and industrial innovation. KBI supports companies driven by strong science and advanced technologies to address critical needs across patients, businesses, and society. Through its Boston office, KBI operates a global investment platform that connects leading U.S. innovation hubs with Korea and the broader Asian market. With a growing international presence and a proven track record of supporting globally scalable companies, KBI remains committed to empowering entrepreneurs and advancing long-term value creation. For more information, visit www.kbic.co.kr .
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the expansion of Orum’s scientific and operational infrastructure, the advancement of programs beyond the preclinical stage, the translation of positive preclinical results to the clinic, the development of new platforms and next-generation degraders and other payloads, the acceleration of next-generation programs, the types of diseases for which Orum’s products might serve as a therapeutic option, and the sufficiency of funding proceeds to allow achievement of goals are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251216175984/en/
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
FAQ**
How does Orum Therapeutics plan to utilize the 145 billion KRW investment from KB Financial Group Inc KB and other investors to advance its DAC programs and expand its scientific infrastructure?
What specific milestones does Orum Therapeutics hope to achieve with the funding from KB Financial Group Inc KB in relation to its ORM-1153 program and other therapeutic pipelines?
Can you elaborate on how the involvement of KB Financial Group Inc KB and other investors enhances Orum's strategic position in the competitive biotech landscape focused on targeted protein degradation?
What measures are in place to manage the risks associated with advancing DAC programs as outlined in the forward-looking statements, particularly with the support of KB Financial Group Inc KB?
**MWN-AI FAQ is based on asking OpenAI questions about KB Financial Group Inc (NYSE: KB).
NASDAQ: KB
KB Trading
0.18% G/L:
$100.115 Last:
172,394 Volume:
$97.94 Open:
